4,208 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Bought by Cornercap Investment Counsel Inc.

Cornercap Investment Counsel Inc. purchased a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,208 shares of the specialty pharmaceutical company's stock, valued at approximately $518,000.

Other large investors also recently modified their holdings of the company. IFP Advisors Inc bought a new position in Jazz Pharmaceuticals in the 4th quarter worth about $25,000. CoreFirst Bank & Trust bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $28,000. Jones Financial Companies Lllp increased its position in shares of Jazz Pharmaceuticals by 75.1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock worth $37,000 after purchasing an additional 130 shares during the last quarter. UMB Bank n.a. raised its stake in Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock valued at $38,000 after purchasing an additional 129 shares in the last quarter. Finally, Lindbrook Capital LLC lifted its position in Jazz Pharmaceuticals by 82.6% during the fourth quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company's stock valued at $48,000 after purchasing an additional 176 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In other news, CMO Robert Iannone sold 7,080 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now directly owns 82,024 shares of the company's stock, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Patricia Carr sold 1,140 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the transaction, the chief accounting officer now owns 7,012 shares in the company, valued at $966,323.72. This represents a 13.98 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,236 shares of company stock worth $3,837,680. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Trading Down 4.5 %

Shares of NASDAQ JAZZ traded down $5.67 during trading hours on Thursday, hitting $120.77. The company's stock had a trading volume of 521,000 shares, compared to its average volume of 743,371. The business has a 50-day simple moving average of $132.54 and a 200-day simple moving average of $122.92. The stock has a market cap of $7.33 billion, a price-to-earnings ratio of 17.01, a P/E/G ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Morgan Stanley reissued an "overweight" rating and issued a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price target for the company from $145.00 to $179.00 in a research report on Friday, March 7th. HC Wainwright lifted their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Piper Sandler reiterated an "overweight" rating and set a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and boosted their target price for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.